NASDAQ:GNCA - Genocea Biosciences, Inc.
$3.47
 $-0.16
-4.41%
12:40PM EDT
2019-07-22
Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one product candidate in Phase III clinical development, GEN-003, an immunotherapy for the treatment of genital herpes. It also has a pre-clinical immuno-oncology program focused on personalized cancer vaccines (GEN-009). The GEN-009 program leverages ATLAS to identify patient neoantigens, or newly formed antigens unique to each patient, that are associated with that individual's tumor. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  GNCA     avg for
industry  
  avg for
sector  
42 stocks weight:  24. 07   217. 37   399. 45  
42 stocks rank:  3. 05 K 1. 27 K 716. 99  
# analyst opinions:  4. 00   13. 21   13. 71  
mean recommendation:  1. 50   2. 10   2. 04  

quick ratio:  2. 36   5. 49   1. 88  
current ratio:  2. 51   5. 87   2. 36  

target price low:  4. 14   83. 44   114. 90  
target price avg:  6. 84   106. 20   137. 90  
target price high:  4. 20   132. 30   158. 97  
1-yr high:  7. 20   111. 86   142. 57  
last close:  3. 63   86. 79   125. 44  
50-day avg:  4. 67   86. 68   122. 63  
200-day avg:  4. 95   89. 22   121. 38  
1-yr low:  2. 30   69. 78   100. 51  
volume:  152. 00 K 2. 62 M 3. 43 M
50-day avg volume:  1. 01 M 3. 20 M 4. 16 M
200-day avg volume:  284. 60 K 2. 99 M 4. 75 M

1-day return:  -0. 82 % -1. 30 % -0. 99 %
this week return:  2. 83 % 0. 45 % -0. 20 %
12-wk return:  -34. 43 % 0. 94 % 4. 84 %
52-wk return:  -35. 29 % -1. 30 % 10. 55 %

enterprise value (EV):  38. 22 M 45. 10 B 122. 38 B
market cap:  51. 00 M 38. 96 B 108. 40 B
EBITDA:  -37. 92 M 4. 20 B 8. 19 B
enterprise multiple (EV/EBITDA):  -1. 01   5. 38   11. 93  
total debt:  15. 55 M 10. 90 B 17. 48 B
debt/equity:  249. 46   57. 18   120. 05  
net income (common):  -27. 49 M 2. 07 B 4. 05 B

shares outstanding:  28. 73 M 538. 09 M 1. 24 B
shares:  7. 95 M 548. 00 M 1. 22 B
shares short:  594. 34 K 10. 98 M 11. 87 M
shares short prior month:  182. 61 K 9. 32 M 12. 05 M
short ratio:  0. 31   5. 60   3. 34  
short % of float:  7. 32 % 6. 48 % 2. 64 %
total cash/share:  2. 07   10. 98   9. 19  
total cash:  29. 04 M 5. 93 B 6. 10 B
free cash flow:  -24. 56 M 2. 92 B 4. 55 B
operating cash flow:  -38. 40 M 3. 80 B 5. 78 B

book value:  0. 39   13. 35   27. 45  
price/book:  9. 21   4. 60   8. 78  
gross profits:  -25. 21 M 7. 44 B 36. 13 B
operating margins:  0. 00 % -308. 40 % -28. 55 %
EBITDA margins:  0. 00 % 13. 17 % 23. 38 %
profit margins:  0. 00 % 10. 44 % 14. 18 %
gross margins:  0. 00 % 35. 80 % 55. 40 %

1-yr max volatility:  0. 00 % --- ---
1-yr mean volatility:  0. 00 % 1. 66 % 1. 03 %

1-yr EPS:  -2. 44   2. 10   4. 23  
forward EPS:  -2. 34   3. 45   7. 10  
P/E:  -1. 49   1. 90   32. 10  
forward P/E:  -1. 55   6. 46   15. 47  
PE/G:  0. 05   0. 70   -0. 54  
growth:  -27. 55 % 265. 63 % 79. 11 %
earnings high:  -0. 39   0. 89   1. 68  
earnings avg:  -0. 66   0. 70   1. 57  
earnings low:  -0. 83   0. 46   1. 46  
revenue high:  -0. 00   2. 57 B 11. 07 B
revenue avg:  -0. 00   2. 51 B 10. 91 B
revenue low:  -0. 00   2. 45 B 10. 73 B
return on assets:  -52. 30 % -2. 34 % 5. 28 %
return on equity:  -264. 27 % -90. 08 % 133. 53 %

beta (1yr vs S&P500):  0. 63   1. 27   0. 91  
sharpe (1yr):  0. 05   0. 16   0. 77  

held % insiders:  11. 14 % 6. 06 % 3. 29 %
held % institutions:  52. 11 % 78. 22 % 69. 37 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-21 : GNCA
.    101.507 =       101.507 :: --> INITIAL WEIGHT <--
.    - 2.439 =        99.068 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 1.994 =        197.55 :: P/E factor
.    x 2.074 =       409.768 :: PE/G factor
.    x 1.268 =       519.549 :: beta factor
.    x 0.654 =       339.533 :: sharpe factor
.    x 2.427 =       824.127 :: current ratio factor
.    x 1.318 =      1086.305 :: quick ratio factor
.    x 1.918 =        2083.6 :: short ratio factor
.    x 1.102 =      2295.146 :: price-to-book factor
.    x 1.881 =      4316.849 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.121 =      9155.143 :: sector+industry 1-year gains factor
.    x 1.009 =      9241.458 :: industry 12-weeks return factor
.    x 1.308 =     12086.797 :: industry 2-weeks return factor
.    x 0.988 =     11938.806 :: "drift" penalty 1 days ago
.    / 2.212 =      5397.369 :: overall "drift" factor
.    x 0.677 =      3652.699 :: largest single-day jump factor
.    x 0.074 =       269.572 :: low price factor
.      x 2.0 =       539.061 :: notable returns + performance factor
.                               --> PROJECTIONS <--
.    x 0.763 =       411.256 :: forward EPS factor
.    x 0.914 =       375.825 :: forward P/E factor
.    x 1.185 =       445.245 :: industry recommendation factor
.    x 2.642 =      1176.156 :: company recommendation factor
.    x 1.003 =      1179.409 :: factor historical industry gain for week 29
.   x 10.529 =     12418.356 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =        10.556 :: reduced for readability
.   + 13.518 =        24.074 :: add/subtract for investor sentiment
.                               --> FINAL WEIGHT <--
.                     24.074 :: FINAL WEIGHT for NASDAQ:GNCA


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org